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Abstract
Previous work has suggested that central-line-associated bloodstream infection (CLABSI) is associated with increased costs and risk of
mortality; however, no studies have looked at both total and variable costs, and information on outcomes outside of the intensive-care unit
(ICU) is sparse. The aim of this study was to determine the excess in-hospital mortality and costs attributable to CLABSI in ICU and non-
ICU patients. We conducted a retrospective cohort and cost-of-illness study from the hospital perspective of 398 patients at a tertiary-care
academic medical centre from 1 January 2008 to 31 December 2010. All CLABSI patients and a simple random sample drawn from a list of
all central lines inserted during the study period were included. Generalized linear models with log link and gamma distribution were used to
model costs as a function of CLABSI and important covariates. Costs were adjusted to 2010 US dollars by use of the personal consumption
expenditures for medical care index. We used multivariable logistic regression to identify independent predictors of in-hospital mortality.
Among both ICU and non-ICU patients, adjusted variable costs for patients with CLABSI were c. $32 000 (2010 US dollars) higher on
average than for patients without CLABSI. After we controlled for severity of illness and other healthcare-associated infections, CLABSI was
associated with a 2.27-fold (95% CI 1.15–4.46) increased risk of mortality. Other healthcare-associated infections were also signiﬁcantly
associated with greater costs and mortality. Overall, CLABSI was associated with signiﬁcantly higher adjusted in-hospital mortality and total
and variable costs than those for patients without CLABSI.
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Introduction
Central lines constitute an important part of the treatment and
management plan for patients who require long-term dialysis,
nutritional support, or administration of medications such as
antibiotics or chemotherapeutic agents. Although the addi-
tional vascular access allowed by these devices improves the
ability to administer multiple therapies, there is also an
increased risk of infection. Patients who require long-term
venous access at baseline are sicker and require more care
than patients without a central line, and the development of a
bloodstream infection may result in substantial increases in
cost and the risk of mortality [1].
There are c. 90 000 new central-line-associated blood-
stream infections (CLABSIs) in the USA each year,
accounting for between 600 million and 2.7 billion US
dollars in annual direct costs [2]. Since 2008, the Center
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for Medicare and Medicaid Services has no longer reim-
bursed the costs of additional care required to treat certain
conditions (‘never events’) that develop in the hospital,
including CLABSIs and other catheter-associated infections
[3]. Reduced reimbursement places a signiﬁcant ﬁnancial
burden on hospitals, particularly tertiary-care facilities,
which tend to have higher rates of CLABSI, owing to the
more severe case mix and consequent greater device use
rates [4]. Given the increased ﬁnancial burden, information
regarding the potentially avoidable cost of CLABSI from the
hospital perspective is critical for future evaluations of the
cost-effectiveness of candidate interventions to reduce the
incidence of CLABSI.
Economic evaluations of CLABSI have generated estimates
that vary widely, depending on the deﬁnition of the infection,
outcome variable, and study design [5–11]. Most published
studies documenting the cost of CLABSI have not distinguished
ﬁxed from variable costs. However, as has been previously
discussed, including ﬁxed costs in estimates of the excess cost
of healthcare-associated infection (HAI) may lead to an overly
optimistic estimation of how much money can be saved as a
result of infection control interventions [10,12]. In addition,
few studies have evaluated economic or clinical outcomes,
including mortality [1,7,13,14], outside of the intensive-care
unit (ICU). Therefore, the objective of this study was to
examine the relationship between CLABSI and total and
variable inpatient costs, as well as in-hospital mortality and 30-
day re-admission rates, in patients in ICU and non-ICU
settings.
Methods
Study design and data sources
The purpose of this study was to estimate the burden of
illness from the hospital perspective and other outcomes
related to CLABSI. We conducted a retrospective cohort
study of 398 patients hospitalized at the University of
Rochester Medical Center, a tertiary-care, academic medical
centre in Rochester, New York, between 1 January 2008 and
31 December 2010. Patients were eligible for the study if they
had a new central line inserted during hospitalization, but
were excluded if the new line was a replacement for an
infected line that was present on admission. Clinical informa-
tion was collected from electronic and paper medical records
with a structured data collection tool by trained reviewers.
Infection control data and administrative data on hospital
costs, charges, International Classiﬁcation of Diseases, Revi-
sion 9 (ICD-9) codes and diagnosis-related groups (DRGs)
were obtained electronically.
Patient selection
We used radiological data to identify all patients who had
central lines inserted during a hospitalization during the study
period, as central lines required radiographic conﬁrmation
before being approved for use. Patients who developed
CLABSI were identiﬁed through the National Healthcare
Safety Network (NHSN) database used by the infection
control program to track all CLABSIs in the facility. Patients
met the deﬁnition of CLABSI if they had a line in place on the
day before or on the day of a positive blood culture and either:
(i) had a recognized pathogen cultured from one or more
blood samples that could not be attributed to infection at
another site; or (ii) had a commensal organism isolated from at
least one blood sample and at least one sign or symptom (fever
of >38°C, chills or hypotension) that was not attributable to an
infection at another site [15]. All CLABSI cases were reviewed
by trained infection preventionists and conﬁrmed by the
hospital epidemiologist, a board-certiﬁed infectious diseases
physician.
From the list of all central lines inserted in the institution
during the study period, we ﬁrst identiﬁed patients who
developed CLABSI during admission (‘exposed’). All lines in
which CLABSI did not develop were considered as potential
control lines, except those contributed by patients who were
already chosen as ‘exposed’. From this list of eligible ‘unex-
posed’ lines, a simple random sample was chosen with a
random number generator. All CLABSI patients and the
selected ‘unexposed’ patients were included in the cohort, and
were followed forward to determine outcomes. Patients may
have had multiple qualifying lines inserted during the study
period. For CLABSI cases, we chose the line that was
associated with the infection. For control lines, we randomly
selected from all eligible lines. Once a line was selected, all
remaining lines for that patient were removed from the eligible
pool.
Outcome assessment
The primary outcome of this study was inpatient costs. Direct
inpatient costs can be divided into ﬁxed costs and variable
costs. Fixed costs are those that cannot be avoided in the
short term, and include things such as facility maintenance,
equipment, and labour. In contrast, variable costs, such as
those for drugs and consumables, can be avoided and are
therefore more relevant to policy-makers in the realm of
hospital-acquired infections [12]. We modelled both total
(ﬁxed and variable) costs and variable costs alone, which were
generated by hospital accountants using micro-costing meth-
ods for all services and goods consumed during hospitalization
[16]. Costs for patients who were hospitalized in 2008 or 2009
were adjusted to 2010 US dollars with the personal consump-
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tion expenditures index, a price index constructed by the US
Bureau of Economic Analysis that improves upon the com-
monly used medical component of the consumer price index
by including third-party payers and allowing for substitution
within the bundle of goods and services on which the index is
calculated [17].
The secondary outcomes in this study were all-cause in-
hospital mortality and 30-day re-admission rate. CLABSI-
speciﬁc mortality and re-admission were not collected,
because of the subjectivity in determining cause of death and
because of the unavailability of information on reason for re-
admission. In-hospital mortality was deﬁned dichotomously as
death from any cause during hospitalization. Re-admission was
deﬁned dichotomously as re-admission to the University of
Rochester Medical Center for any reason within 30 days of
discharge after the index hospitalization. Information on
admissions to other hospitals was not available, but the
frequency is likely to be low.
Covariates
Factors shown to independently predict cost in previous
economic evaluations of CLABSI were collected. In order to
account for patients who require more care, we collected
information to compute the Acute Physiologic and Chronic
Health Evaluation (APACHE) II score [18] at the time of line
insertion (3 days) and the Deyo–Charlson Comorbidity
Index [19]. APACHE II was originally developed for use in the
ICU, but has been shown to predict mortality in both ICU and
non-ICU patients with bacteraemia [20]. We collected infor-
mation on DRGs, which is a method of classifying patients
according to severity and resource utilization during hospital-
ization [21]. Because the DRG system used to classify patients
varies by payer, the DRG system was recorded. The devel-
opment of other HAIs during hospitalization was identiﬁed on
the basis of clinical diagnosis recorded in the medical chart.
Major surgical procedures were identiﬁed from ICD-9 codes,
and classiﬁed by use of the Healthcare Utilization Project
procedure classiﬁcation tool [22].
The presence of multiple catheters was deﬁned as multiple
catheters in place at any time during the study period,
regardless of duration. For each patient, the number of days
spent in an ICU and the number of days spent in an
intermediate-care (‘step-down’) unit were tabulated. The
overall length of stay was computed as the time from
admission to discharge for all patients, and is the sum of days
spent in the ICU, step-down units, and on general medical
ﬂoors. Any ICU stay was deﬁned as a dichotomous variable;
patients with one or more days spent in the ICU were
considered to be ICU patients. Missing ICD-9 codes or lack of
documentation in the chart was presumed to indicate the lack
of the procedure or condition of interest. There were no
other missing values. This study was reviewed and approved
by the University of Rochester’s Research Subjects Review
Board.
Data analysis
Multivariable cost models were implemented in Stata 12
(Stata, College Station, TX, USA). All other analyses were
conducted with SAS V9.3 (SAS, Cary, NC, USA). The clinical
characteristics and outcomes of patients with and without
CLABSI were compared across groups by the use of chi-
square tests for categorical variables and Wilcoxon rank sum
tests for continuous variables.
Total costs and variable costs (2010 US dollars) were
modelled with multivariable generalized linear models with a
log link, which allows modelling of skewed data without the
bias associated with retransformation or the difﬁculty of
interpreting estimates on the log scale [23]. Modiﬁed Park
post-tests were used to conﬁrm that, in both models, the
gamma distribution was the most suitable choice [24]. All non-
outcome variables (shown in Table 1) were included in cost
models, and retained regardless of statistical signiﬁcance,
except for overall length of stay and death, which were
considered to be intermediary variables. Average marginal (for
continuous variables) or incremental (for categorical variables)
effects were computed with the ‘margins’ command in Stata.
Separate cost models were constructed for ICU patients and
non-ICU patients.
Multivariable logistic regression was used to model the risk
of in-hospital mortality and 30-day re-admission as a function
of CLABSI and other covariates. Covariates were identiﬁed for
the model on the basis of an association with CLABSI in the
bivariate analysis at p <0.20, and were retained in the model
regardless of statistical signiﬁcance. Variance inﬂation factors
were evaluated to detect problems with predictor collinearity
[25].
Results
On average, CLABSI patients were more likely to have had
other HAIs (67.5% vs. 30.4%, p 0.01) during hospitalization
than non-CLABSI patients (Table 1). CLABSI patients had a
greater severity of underlying illness as measured by the
APACHE II score at the time of line insertion, but there was
no difference in the Deyo–Charlson Comorbidity Index.
Patients also spent more time in the ICU and step-down
units, but there was no difference in patient race. The
unadjusted difference in variable hospital costs between
patients with CLABSI and those without CLABSI was
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c. $56 800. CLABSI patients were at higher risk of dying in the
hospital, but 30-day re-admission rates were similar between
the two groups.
Table 2 shows the characteristics of CLABSI patients in the
cohort. The median (interquartile range) pre-CLABSI length of
stay and post-CLABSI length of stay were 24.0 days
(30.0 days) and 18.0 days (27.0 days), respectively. The most
commonly isolated pathogens were coagulase-negative
Staphylococcus (32.5%) and Candida species (16.8%). CLABSI
complications, such as bacteraemia, occurred in c. 10% of
patients.
Table 3 shows results from the multivariable cost models
for non-ICU patients. Because the models used a log link
function, the coefﬁcients can be interpreted as the percentage
change in costs for each one-unit increase in the independent
variable. After the effects of severity, presence of another HAI
and other covariates had been accounted for, non-ICU
patients with CLABSI had a 76% greater total cost than non-
ICU patients without CLABSI, which translates to c. $50 000.
Similarly, the presence of CLABSI was associated with 80%
greater variable costs than for patients without CLABSI,
corresponding to c. $33 000 in excess variable cost in our
sample. The presence of another HAI was signiﬁcantly
associated with a 75% increase in variable costs. As shown in
Table 4, the absolute excess costs were nearly identical among
ICU patients. CLABSI was associated with c. $49 600 in excess
total costs and $32 400 in excess variable costs. However, this
resulted in smaller incremental effects, because total costs
were much higher for ICU patients than for non-ICU patients.
Each day spent in the ICU was associated with c. $1700 in
additional variable costs.
Between 1 January 2008 and 31 December 2010, 74
patients died during hospitalization, resulting in a mortality rate
of 18.6%. The results of the multivariable logistic regression
model for in-hospital mortality are shown in Table 5. In
bivariate analysis, CLABSI patients were at a four-fold
increased risk of dying. On multivariable analysis, only CLABSI,
other HAI and APACHE II score were independent predictors
of death. After other HAI, APACHE II and the presence of
multiple catheters had been controlled for, CLABSI patients
had a 2.27-fold (95% CI 1.15–4.46) greater risk of mortality
than non-CLABSI patients. There was no difference in the 30-
day re-admission rate on bivariate or multivariable (data not
shown) analyses.
Discussion
There has been substantial research on the design and
evaluation of interventions to reduce the risk of CLABSI,
and progress has been observed. The most recent NHSN
report shows a 58% decrease in ICU CLABSI rates from 2001
to 2008 [26]. Despite recent successes in the reduction of
TABLE 2. Characteristics of patients with central-line-asso-
ciated bloodstream infection (CLABSI) (n = 197)
Characteristic n %
CLABSI pathogen
Coagulase-negative Staphylococcus 64 32.5
Candida species 33 16.8
Klebsiella species 26 13.2
Escherichia coli 11 5.6
Enterococcus faecium 13 6.6
Other Enterococcus 36 18.3
Methicillin-resistant Staphylococcus aureus 13 6.6
Any CLABSI complicationsa during hospitalization 20 10.2
Recurrent bacteraemia 11 5.6
Other 9 4.6
Median IQR
Pre-CLABSI LOS (days) 24.0 30.0
Post-CLABSI LOS (days) 18.0 27.0
Total LOS (days) 43.0 54.0
CLABSI, central-line-associated bloodstream infection; IQR, interquartile range;
LOS, length of stay.
aDeﬁned as infection with same pathogen between 72 h before and 30 days after
CLABSI diagnosis. Other complications included endocarditis, osteomyelitis, septic
arthritis, meningitis, and septic thrombophlebitis.
TABLE 1. Characteristics of the study population (n = 398)
Characteristic CLABSI No CLABSI p
No. of patients 197 201
Age (years), median (IQR) 58.0 (26.0) 59.0 (26.0) 0.30
Males, n (%) 131 (66.5) 116 (57.7) 0.07
Race, n (%)
White 138 (70.1) 155 (77.1) 0.26
Black 38 (19.3) 31 (15.4)
Other 21 (10.7) 15 (7.5)
Other HAI, n (%) 133 (67.5) 61 (30.4) 0.01
Dialysis, n (%) 48 (24.4) 28 (13.9) 0.01
Major surgery, n (%) 113 (57.4) 85 (42.3) <0.01
Multiple catheters, n (%) 66 (33.5) 17 (8.5) <0.0001
Overall length of stay
(days), median (IQR)
43.0 (54.0) 13.0 (18.0) <0.0001
1–7 1 (0.50) 49 (24.4)
>7 196 (99.5) 152 (75.6)
Days in step-down care, n (%)
None 121 (61.4) 174 (86.6) <0.0001
1–7 28 (14.2) 18 (9.0)
>7 48 (24.4) 9 (4.5)
Days in the ICU, n (%)
None 101 (51.3) 147 (73.1) <0.0001
1–7 33 (16.8) 32 (15.9)
>7 63 (32.0) 22 (11.0)
APACHE II score,
median (IQR)
14.0 (7.0) 11.0 (7.0) <0.0001
CCI, median (IQR) 2.0 (3.0) 2.0 (2.0) 0.23
DRG weight, median (IQR)
CMS-DRG (n = 179) 5.16 (8.59) 1.79 (2.75) <0.0001
AP-DRG (n = 177) 12.1 (23.4) 4.36 (7.88) <0.0001
APR-DRG (n = 42) 9.34 (21.3) 3.45 (4.68) <0.01
Outcomes














30-day re-admission, n (%) 47 (33.3) 52 (28.4) 0.34
n at risk of re-admission 141 183
In-hospital mortality, n (%) 56 (28.4) 18 (9.0) <0.0001
APACHE II, Acute Physiologic and Chronic Health Evaluation version II; CCI,
Carlson Comorbidity Index; CLABSI, central-line-associated bloodstream infec-
tion; DRG, diagnosis-related group; HAI, healthcare-associated infection; ICU,
intensive-care unit; IQR, interquartile range; USD, United States dollars.
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CLABSI rates in the ICUs of those facilities contributing data
to the NHSN, signiﬁcant work remains to reduce the impact of
these infections on our healthcare system. In an effort to
incentivize quality improvement, Medicare no longer reim-
burses for CLABSIs and other HAIs. However, studies suggest
that not all HAIs are preventable [27,28], and hospitals must
absorb the costs of CLABSIs for patients with Medicare
coverage. Therefore, estimates of the excess cost and
mortality potentially attributable to CLABSIs are critical to
estimate the ﬁnancial impact of reduced reimbursement and to
evaluate the potential cost savings of new interventions.
We observed that CLABSI was associated with signiﬁcantly
higher total and variable costs than those for patients without
CLABSI. On average, CLABSI was associated with c. $33 000
in excess variable costs, regardless of whether patients were in
the ICU or not. This ﬁgure is similar to some previously
published estimates. Pittet et al. [6] examined excess costs of
nosocomial bloodstream infections in a matched case–control
study of surgical ICU patients, and observed c. $41 000 (1994
US dollars) in excess total costs. In another analysis of
nosocomial bloodstream infections in the ICU setting, Digio-
vine et al. [8] observed that survivors with infections had more
than $34 000 (1995 US dollars) in excess costs relative to
patients without bloodstream infections. However, both
estimates arise from matched studies composed of ICU
patients who did not die during hospitalization. Both studies
analysed total direct costs rather than variable costs, and were
also conducted almost 20 years ago, limiting comparability
with our results.
Most of the previous research on the economics and
outcomes of CLABSI has been conducted exclusively among
ICU patients. Our study was conducted among both ICU and
non-ICU (general medical and step-down) patients of a large,
tertiary-care, academic hospital. We observed that, among
ICU patients, each additional day of ICU stay was associated
with c. $1700 in excess variable costs. Each day in the step-
down unit stay added c. $1280 in variable costs for ICU
patients, but there was no increase in cost per step-down day
Characteristic
Adjusteda total costs (2010 USD) Adjusteda variable costs (2010 USD)
Coefﬁcient Excess cost p Coefﬁcient Excess cost p
CLABSI 0.762 50 094 <0.0001 0.797 32 984 <0.0001
Other HAI 0.755 53 068 <0.0001 0.752 33 447 <0.0001
Major surgery 0.18 12 755 0.05 0.203 9524 0.03
APACHE II, per point 0.029 2121 <0.01 0.030 1384 <0.01
Age, per year 0.009 639 0.01 0.008 383 0.01
APACHE, Acute Physiologic and Chronic Health Evaluation; CLABSI, central-line-associated bloodstream infection; HAI,
healthcare-associated infection.
aAll costs were modelled by generalized linear regression with log link and gamma distribution. In addition to the
variables listed in the table, estimates were also adjusted for gender, race, Charlson Comorbidity Index, number of days
in a step-down unit, presence of multiple catheters, diagnosis-related group (DRG) weight, and DRG system (AP-DRG,
CMS-DRG, or APR-DRG).
TABLE 3. Estimated adjusted
excess total and variable inpatient
hospital costs (2010 US dollars
(USD)) for patients with no inten-
sive-care unit stay (n = 248)
Characteristic
Adjusteda total costs (2010 USD) Adjusteda variable costs (2010 USD)
Coefﬁcient Excess cost p Coefﬁcient Excess cost p
CLABSI 0.198 49 618 0.04 0.211 32 412 0.03
Other HAI 0.561 122 217 <0.0001 0.595 78 832 <0.0001
Multiple catheters 0.362 96 000 <0.01 0.386 63 096 <0.01
ICU stay, per day 0.011 2921 <0.0001 0.011 1726 <0.0001
Step-down stay, per day 0.008 2111 <0.0001 0.008 1280 <0.0001
CLABSI, central-line-associated bloodstream infection; HAI, healthcare-associated infection.
aAll costs were modelled by generalized linear regression with log link and gamma distribution. In addition to the
variables listed in the table, estimates were also adjusted for gender, age, race, major surgical procedure, Acute
Physiologic and Chronic Health Evaluation (APACHE) II score, Charlson Comorbidity Index, diagnosis-related group
(DRG) weight, and DRG system (AP-DRG, CMS-DRG, or APR-DRG).
TABLE 4. Estimated adjusted
excess total and variable inpatient
hospital costs (2010 US dollars
(USD)) for patients with any inten-
sive-care unit (ICU) stay (n = 150)
TABLE 5. Multivariable logistic regression of in-hospital






CLABSI 4.04 (2.27–7.17) 2.27 (1.15–4.46)
Other HAI 4.19 (2.36–7.45) 2.62 (1.30–5.30)
Multiple catheters 4.77 (2.76–8.26) 1.92 (0.97–3.80)
APACHE II score,
per 5 points
2.02 (1.63–2.51) 1.71 (1.33–2.20)
Step-down stay, per 7 days 1.15 (1.05–1.25) 1.09 (0.99–1.20)
ICU stay, per 7 days 1.08 (1.01–1.15) 1.08 (0.98–1.18)
Dialysis 2.97 (1.67–5.22) 1.05 (0.51–2.18)
OLOS, per 7 days 1.05 (1.02–1.07) 0.97 (0.92–1.02)
Major surgery 1.24 (0.75–2.05) 0.72 (0.38–1.37)
Male sex 0.85 (0.52–1.46) 0.71 (0.39–1.29)
APACHE II, Acute Physiologic and Chronic Health Evaluation Version II; CLABSI,
central-line-associated bloodstream infection; HAI, healthcare-associated infec-
tion; ICU, intensive-care unit; OLOS, overall length of stay.
aAdjusted for the presence of multiple catheters, which was classiﬁed as a
confounder based on a 10% change in the parameter estimate for CLABSI when
removed from the model.
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among non-ICU patients. Development of another HAI was
associated with the largest incremental increase in variable
costs: approximately $34 000 and $79 000 for non-ICU and
ICU patients, respectively. As expected, APACHE II score was
strongly associated with cost, with each additional point
equating to c. $1300 in extra variable costs, but only among
non-ICU patients.
In our study, patients with CLABSI were more than twice as
likely to die as patients without CLABSI, even after APACHE II
score and the presence of other HAIs had been controlled for.
An association between CLABSI and crude in-hospital mor-
tality has been observed in several studies [1,7,13,14,29], but,
in some cases, CLABSI has not remained an independent
predictor of mortality in multivariable analysis [7,29]. This may
be attributable to a small number of CLABSI cases, resulting in
reduced power to detect true associations. In the study by
Dimick et al. [29], for example, the mortality among the nine
CLABSI patients was 56%, as compared with 21% among 251
non-CLABSI patients (p 0.02). After the effects of APACHE III
score had been controlled for, CLABSI was no longer an
independent predictor (adjusted OR 4.3, 95% CI 0.9–19.9).
There was no difference in the 30-day re-admission rates
between patients with and without CLABSI (33.3% vs. 28.4%,
respectively, p 0.34), even after removal of those not at risk of
re-admission (i.e. those who died).
The primary limitation of this study is the inability to
account for the timing of infection in our cost models.
Recently, the importance of the time-dependent nature of
infection has been highlighted in several papers and editorials
[10,12,30,31]. However, our data did not allow us to
differentiate between costs that occurred before and after
the CLABSI event. Although this most likely results in an
overestimation of potential cost savings in the context of an
intervention, information about the total and variable costs for
patients who develop CLABSI is still useful for hospital
administrators. In addition, this is a limitation that few studies
examining the relationship between HAI and inpatient costs
have been able to overcome.
Residual confounding is always a concern in observational
research, and there is a possibility that the observed differ-
ences in cost are attributable to some unmeasured factor,
rather than a true difference in costs and mortality resulting
from CLABSI infection. Sample restriction, matching and
adjustment are common methods to control for measured
confounders, but none of these methods addresses confound-
ers that are unobserved. Because of the small sample size, we
chose to use multivariable adjustment to avoid excluding any
patients. Randomization and instrumental variable analysis are
both superior methods for addressing confounding resuting
from measured and unmeasured variables, but were not
feasible in this study.
This study is also limited by a potential lack of generaliz-
ability. We used data from an academic medical centre, which
may be more likely to use newer and more expensive
treatments as part of routine care. Therefore, our results may
not be applicable to smaller community hospitals or to Federal
institutions. In addition, there may be signiﬁcant variability in
micro-costing methods across institutions, resulting in sub-
stantially different estimates of cost. However, the use of the
relative measure (e.g. an 80% increase in variable costs for
CLABSI patients in the non-ICU setting) rather than the
absolute dollar estimate should prove more applicable across a
range of study settings. We lacked re-admission data for other
institutions; however, the rate of switching between healthcare
facilities is small and unlikely to differ between CLABSI and
non-CLABSI patients. Finally, we used the NHSN deﬁnition of
CLABSI, which is a surveillance deﬁnition and is not as
restrictive as the clinical deﬁnition of CRBSI. This may have
resulted in some patients with bloodstream infections unre-
lated to their central lines being classiﬁed as ‘exposed’.
However, our deﬁnition is consistent with the case deﬁnition
commonly employed by hospitals for surveillance purposes.
This study also has several strengths. To the best of our
knowledge, it is the ﬁrst study of CLABSI to analyse total and
variable costs separately. In addition, this is one of the few
studies that has not focused exclusively on ICU residents,
allowing for wider generalization than previous estimates of
excess cost. We used a robust multivariable modelling
methodology to model costs as a function of the presence
and severity of underlying illness, DRG, and other factors that
inﬂuence hospital costs. We also were able to incorporate
both administrative and clinical data, manually collecting the
information necessary to compute the APACHE II score,
which is not traditionally available in electronic health data.
In summary, we observed that CLABSI was associated with
signiﬁcantly higher hospital costs and risk of in-hospital
mortality. These costs represent a substantial burden to
hospitals, particularly for patients covered by Medicare.
Continued reductions in CLABSI rates should help to offset
some, but not all, costs for these patients. Future work should
examine costs while accounting for timing of infection in both
ICU and non-ICU patients.
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